Allergan Inc. racked up another success in expanding the therapeutic label for Botox Jan. 18 as FDA approved the product for treating idiopathic overactive bladder (OAB) in patients who are intolerant of or had inadequate response to anticholinergic drugs. Botox, best known for its cosmetic use as a wrinkle reducer, now has eight therapeutic indications in the U.S. and is approved for 26 indications in more than 85 countries, according to the company.
The latest indication is the second for Botox in OAB. In 2011, the injectable drug was approved for a narrower...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?